Synairgen Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 11
Employees
  • Stock Symbol
  • SNG
Stock Symbol
  • Share Price
  • $2.06
  • (As of Monday Closing)

Synairgen General Information

Description

Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, LOXL2 inhibitor, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Stock Exchange
LON
Primary Office
  • Mailpoint 810
  • Southampton General Hospital, Tremona Road
  • Southampton SO16 6YD
  • England, United Kingdom
+44 023 0000 0000

Synairgen Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synairgen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.06 $2.13 $0.41 - $3.43 $411M 200M 1.97M -$0.06

Synairgen Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 70,787 3,969 11,444 9,340
Revenue 0 0 140 6,470
EBITDA (9,369) (5,938) (5,457) 2,110
Net Income (7,649) (4,957) (4,402) 2,267
Total Assets 16,940 5,338 8,634 10,354
Total Debt 256 430 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Synairgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synairgen‘s full profile, request access.

Request a free trial

Synairgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in th
Drug Discovery
Southampton, United Kingdom
11 As of 2019
00000
000000000 00000

000000 0

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000 000000000
London, United Kingdom
00 As of 0000
00000
000000000 00000

000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000000000000
Ann Arbor, MI
00 As of 0000
00000
000000000 - 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synairgen Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verona Pharma Corporation London, United Kingdom 00 00000 000000000 00000
000000 Venture Capital-Backed Ann Arbor, MI 00 00000 000000000 - 00000
0000000000 Corporate Backed or Acquired Basel, Switzerland 000000&0
0000000000 0000000 Venture Capital-Backed Brighton, United Kingdom 00 000.00 00000000000 000.00
00000000 Formerly VC-backed Florham Park, NJ 0 00000000
You’re viewing 5 of 13 competitors. Get the full list »

Synairgen Executive Team (5)

Name Title Board Seat Contact Info
Richard Marsden Chief Executive Officer & Board Member
John Ward Chief Financial Officer, Finance & Board Member
Phillip Monk Ph.D Chief Scientific Officer & Board Member
Donna Davies Co-Founder
Ratko Djukanovic MD Co-Founder
To view Synairgen’s complete executive team members history, request access »

Synairgen Board Members (10)

Name Representing Role Since
David Campbell Synairgen Board Member 000 0000
Iain Buchanan Self Board Member 000 0000
John Ward Synairgen Chief Financial Officer, Finance & Board Member 000 0000
Phillip Monk Ph.D Synairgen Chief Scientific Officer & Board Member 000 0000
Richard Marsden Synairgen Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Synairgen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synairgen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Synairgen‘s full profile, request access.

Request a free trial